Acrivon Therapeutics Appoints Jean-Marie Cuillerot, M.D., as Chief Medical Officer

Core Insights - Acrivon Therapeutics has appointed Dr. Jean-Marie Cuillerot as Chief Medical Officer, bringing over 20 years of oncology drug development experience to the company [1][2] - The company is focused on developing precision oncology medicines using its proprietary platform, Acrivon Predictive Precision Proteomics (AP3), which matches patients to therapies based on tumor sensitivity [1][6] Company Developments - Dr. Cuillerot has a strong track record in advancing oncology drugs from early development to regulatory approval, having previously held leadership roles at Dragonfly Therapeutics and Agenus [2][3] - Acrivon has also announced other personnel updates, including Dr. Erick Gamelin transitioning to Chief Development Officer and the appointments of Dr. Karl Hsu and Ms. Rajshree Kandadai to senior roles [4][5] Product Pipeline - Acrivon's lead candidate, ACR-368, is a selective small molecule inhibitor targeting CHK1 and CHK2, currently in a potentially registrational Phase 2 trial for multiple tumor types [6] - The company has received Fast Track designation from the FDA for ACR-368 as a monotherapy for patients with platinum-resistant ovarian or endometrial cancer [6] - Acrivon is also developing ACR-2316, a selective dual WEE1/PKMYT1 inhibitor, as part of its preclinical pipeline [6]